Who's bested two Big Pharmas?

Sobi is the most respected pharma among bleeding disorders patient groups, according to the latest report from PatientView.

The Sweden-based rare diseases specialist took top spot ahead of Roche/Genentech/Chugai in second place, and Novo Nordisk in third. The top three companies were the same whether patient groups were asked to rate the corporate reputation of pharmas they were “working with” or pharmas they were “familiar with”.

Sobi’s haematology portfolio includes extended half-life recombinant replacement clotting factor treatments for haemophilia A and haemophilia B, as well as treatments for thrombocytopenia, rare kidney diseases, diffuse large B-cell lymphoma and myelofibrosis.